Alves Anelise Maria Costa Vasconcelos, Cruz-Martins Natália, Rodrigues Célia Fortuna
Institute of Health Sciences, University of International Integration of Afro-Brazilian Lusophony, Av. da Abolição, 3-Centro, Redenção 62790-000, Ceará, Brazil.
LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
J Fungi (Basel). 2022 Jun 25;8(7):669. doi: 10.3390/jof8070669.
is still the major yeast causing human fungal infections. Nevertheless, in the last decades, non- species (NCACs) (e.g., , , and ) have been increasingly linked to sp. infections, mainly in immunocompromised and hospitalized patients. The escalade of antifungal resistance among sp. demands broadly effective and cost-efficient therapeutic strategies to treat candidiasis. Marine environments have shown to be a rich source of a plethora of natural compounds with substantial antimicrobial bioactivities, even against resistant pathogens, such as sp. This short review intends to briefly summarize the most recent marine compounds that have evidenced anti- sp. activity. Here, we show that the number of compounds discovered in the last years with antifungal activity is growing. These drugs have a good potential to be used for the treatment of candidiasis, but disappointedly the reports have devoted a high focus on , neglecting the NCACs, highlighting the need to perform outspreading studies in the near future.
仍然是引起人类真菌感染的主要酵母菌。然而，在过去几十年中，非白色念珠菌（NCACs）（如光滑念珠菌、热带念珠菌和近平滑念珠菌）与念珠菌属感染的关联日益增加，主要发生在免疫功能低下和住院患者中。念珠菌属中抗真菌耐药性的升级需要广泛有效的且具有成本效益的治疗策略来治疗念珠菌病。海洋环境已被证明是大量具有显著抗菌生物活性的天然化合物的丰富来源，甚至对耐药病原体如念珠菌属也有效。这篇简短的综述旨在简要总结最近已证明具有抗念珠菌属活性的海洋化合物。在此，我们表明近年来发现的具有抗真菌活性的化合物数量正在增加。这些药物具有用于治疗念珠菌病的良好潜力，但令人失望的是，报告高度关注白色念珠菌，而忽视了非白色念珠菌，这突出了在不久的将来开展广泛研究的必要性。
